CM
IRON icon

Crestline Management’s Disc Medicine IRON Stock Holding History

Crestline Management’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,057
Closed -$104K – 239
2022
Q2 		$104K Sell
2,057
-26
-1% -$1.15K 0.01% 206
2022
Q1 		$87K Buy
+2,083
New +$109K 0.01% 249

Other funds holding IRON

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
FCOMV
Foresite Capital Opportunity Management V Larkspur, California $33.3M AUM 47.04% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Crestline Management's IRON Position: Q3 2022 in Review

Crestline Management sold out of Disc Medicine (IRON) in Q3 2022, closing a stake of 2,057 shares — an estimated $104K sold.

Crestline Management first reported a position in IRON in Q1 2022 and held it in 2 quarters. The position peaked at $104K in Q2 2022. 44 funds tracked by Wall St. Rank hold IRON as of Q3 2022.

  • Crestline Management reported no remaining Disc Medicine position as of Q3 2022 after selling out during the quarter.
  • Crestline Management sold 2,057 Disc Medicine shares in Q3 2022, an estimated $104K.
  • Crestline Management first reported a position in Disc Medicine in Q1 2022 and held it in 2 quarters.
  • Crestline Management's Disc Medicine position peaked at $104K in Q2 2022.
  • 44 funds tracked by Wall St. Rank held Disc Medicine as of Q3 2022.

Based on Crestline Management's 13F filing for Q3 2022, filed 14 Nov 2022.